Fusf presentation to share 11.20

“Without health there can be no happiness.”

Two Stories
Focused Ultrasound
Technology
Focused Ultrasound
Foundation

Focused Ultrasound
Early stage, revolutionary, noninvasive therapeutic technology
Alternative or adjunct
 Surgery
 Radiation therapy
 Drug delivery
Transform treatment
 Benign and malignant tumors
 Metastatic cancer
 Parkinson‟s disease & epilepsy
 Back pain, hypertension

Early Stage
MR 30 years ago
 Unknown
 Revolutionized diagnoses
 Affects everyone
Focused Ultrasound today
 Unknown; “Medicine‟s Best Kept Secret”
 As important to therapy as MR is to diagnoses
 In 10 years, may affect everyone
Infancy
 Not science fiction
 Real today

Essential Tremor Treatment

Awake, no anesthesia
No incisions
No burr holes
No electrodes
No infection
No blood clots
No brain damage

Uterine Fibroid
Hysterectomy








Major surgery
General anesthesia
Painful
Hospitalization
6 weeks recovery
Side effects
No more children

Focused Ultrasound








Noninvasive, no incision
Conscious sedation
Minimal discomfort
Outpatient
1 day recovery
No side effects
Preserved fertility

Uterine Fibroid
Pre-treatment

9 months post-treatment

Breast Cancer
Pre-treatment

Two weeks post treatment

What is Focused Ultrasound?
How does it work?

Marriage of Two Innovative Technologies
Focused ultrasound
 Treat tissue deep in body non-invasively

Marriage of Two Innovative Technologies
Magnetic resonance (MR) or ultrasound (US) imaging
 Identify and target tissue to be treated
 Guide and control treatment in real time
 Immediate confirmation of effectiveness

Focused Ultrasound: The Principle
Analogous to a magnifying glass focusing rays of the sun…

Focused Ultrasound: The Principle
Multiple intersecting beams of ultrasound
 Focused with extreme accuracy (1 mm diameter)
 Target in body
• Individual beams pass harmlessly through adjacent tissue
• Profound effect at point of convergence

Effects at Focal Point
Thermal ablation
Histotripsy
Deliver drugs
Dissolve clots: sonothrombolysis
Radiation sensitization
Drug activity enhancement
Sonodynamic therapy
Coagulate blood vessels
Amplification of cancer biomarkers
Immunomodulation
Neuromodulation
Vasodilation
Vasoconstriction
Variety of effects, variety of disorders
Stem cell delivery

Destroy Tissue: Thermal Ablation
Heating any tissue to 130 F (56 C) for 1 second
 Denatures proteins
 100% cell death: normal and abnormal

Focal Drug Delivery
Deliver drugs in high concentrations
 Precisely where needed, minimizing systemic toxicity

Lipid Microbubbles
Chemotherapeutic agents; genes; growth factors

Focused Ultrasound Procedure
Targeting
Planning
Treating

Confirming

Uterine Fibroids

Essential Tremor

Brain Tumors

Focused Ultrasound vs Radiation
Single treatment
Immediate and verifiable effect
Greater precision and accuracy
Real time localization
No cumulative dose
No limitations on lesion size
No limitations on number of treatments
No secondary malignancies
100% cell death
Sharp margins

Sharp Margins
Liver

Treated

1 mm

Brain

Global Development Landscape
Conceptual

Preclinical

Anecdotal

Pilot

Pivotal

Other Approvals

FDA

Reimbursement

Neurological

Oncological

Musculoskeletal

Essential Tremor
Parkinson‟s Disease
Neuropathic Pain
Brain Tumors
OCD
Epilepsy
Stroke
Hydrocephalus
Trigeminal Neuralgia
Alzheimer‟s Disease
Cancer Pain
Depression

Bone
Prostate Tumors
Thyroid/Parathyroid
Breast Cancer
Pancreas
Soft Tissue
Liver
Kidney
Head, Neck Cancer
Lung
Bladder
Colon
Esophagus

Back Pain
Osteoid Osteoma
Osteoarthritis
Sacroilitis

Women’s Health

Cardiovascular

Miscellaneous

Uterine Fibroids
Uterine Adenomyosis
Breast Fibroadenomas

Hypertension
Atherosclerosis
Atrial Fibrillation
Septal Perforation

Acute Tubular Necrosis
Obesity
Diabetes
Glaucoma
Benign Prostatic Hypertrophy
Ureterocele

Reimbursement
Sparse

Clinical Trials

Regulatory: FDA
Uterine Fibroids
Pain from Bone Metastasis

Anecdotal

Osteoarthritis
Thyroid/Parathyroid Brain Tumors
Hypertension
Breast Tumors
OCD
Pancreatic Tumors
Kidney Tumors
Liver Tumors
Neuropathic Pain
Parkinson‟s Disease Essential Tremor
Soft Tissue Tumors Prostate Cancer
Uterine Adenomyosis

Regulatory: Outside US
Essential Tremor
Parkinson‟s Disease
Neuropathic Pain
Uterine Fibroids
Uterine Adenomyosis
Breast Tumors
Prostate Cancer

Thyroid/Parathyroid
Pain from Bone Metastasis
Pancreatic Tumors
Liver Tumors
Soft Tissue Tumors
Osteoid Osteoma
Back Pain
Kidney Tumors

Preclinical
Hydrocephalus
Epilepsy
Alzheimer‟s Disease
Stroke
Atherosclerosis
Obesity
Atrial Fibrillation
Diabetes
Septal Perforation
Sacroilitis
Trigeminal Neuralgia
Glaucoma
Acute Tubular Necrosis
Benign Prostatic Hypertrophy
Head & Neck Cancer
Lung Cancer
Ureterocele

Conceptual
Cancer Pain
Bladder Cancer
Colon Cancer
Esophageal Cancer
Depression

Imagine the Future
Advances in technology
 Imaging
 Focused ultrasound
 Focal drug delivery
Undreamed-of applications

Magnetic Resonance Imaging
Insert MR videos

Limitations
Scoliosis

Leukemia

Traumatic Injuries

Potential Impact on Millions of People
Urgent need: widespread availability of focused ultrasound
 Saving time, saving lives
Delay results in unnecessary death, disability and suffering
 Countless individuals: friends, family, you

The Problem
Medical device development and adoption slow

Decades: concept to adoption as standard of care

Process, Complicated and Inefficient
Patient
advocacy

Evidence, safety,
efficacy, cost

Technology R&D
IP generation
and protection

Design,
engineering,
manufacturing
Pre-clinical
proof of concept

Regulatory
approval

Marketing,
sales, support

Training and
credentialing

Insurance
reimbursement

Physician and
Scientist education

Physician
advocacy

Organizations with Different Agendas
Patients
Academic research sites
Private philanthropy
Disease specific foundations
NIH
Venture capital, private equity
Industry
FDA
Insurers
Patient advocacy organizations
Medical societies
Treatment facilities
Physicians, numerous specialties

Obstacles
Technical and engineering
Awareness and acceptance, patients and physicians

Cultural and turf issues
Financial
Regulatory
Reimbursement

The Solution
Obscure
No roadmap, examples or formulas

Obligated to invent

The Challenge

"There is nothing more difficult to take in
hand, more perilous to conduct, or more
uncertain in its success, than to take the lead in
the introduction of a new order of things."

It‟s all about the patients

saving time, saving lives

Purpose of the Foundation
Development

Adoption

Millions
of Lives
Improved

Overview
Founded 2006
 Catalyst to accelerate the development and adoption of FUS

Charlottesville based, global impact

Tax exempt, high performance, entrepreneurial
 Market driven, action and results oriented

Essence of activities
 Foster collaboration
 Knowledge: create, aggregate, share

Model
 Venture philanthropy, social entrepreneurship
 Private funding bridges gap between research & treatment

Unique, Hybrid Organization
Device: platform technology
Variety of clinical indicators
Fulfill multiple roles

Focused Ultrasound Foundation

Medical &
Scientific
Society

Manufacturers
Trade
Association

Patient
Advocacy
Organization

Patient
Support
Organization

Research &
Education
Foundation

Vision
Focused Ultrasound





Improve quality of life and longevity
Millions of patients worldwide
Serious medical disorders
Shortest time possible

Mission
Accelerate development of new applications





Fulfill unmet critical medical need
Superior to best current therapies
Reimbursable
Widely available as standard of care

Accelerate adoption as standard of care

Culture
Patient centric
 Uncompromisingly, passionately, obsessively committed to rapidly
improving quality of life

Catalytic, small, nimble, potent
 Reputation, contagious enthusiasm and energy
 Instill in others enthusiasm and energy to precipitate change

Entrepreneurial
 Create reality from imagined future through human action
 Accomplishments exceed assets available

Pioneering
 Pursuit of excellence
 Hard work, risk taking, innovation

Strategic Focus
It's all about the patients: saving time, saving lives
 Litmus test of actions and expenditures

Positioning, Nexus of Organizations
Academic research sites
Venture capital,
Patients
Academic
private equity
research sites
Private philanthropy
Disease specific foundations
Industry
Insurers
NIH
Private
Disease specific
Venture capital, private equity
philanthropy
foundations
Industry
Insurers
FDA
Patients
Patient advocacy organizations
Patient advocacy
Medical societies
organizations
Medical societies
FDA
NIH
Physicians,
Physicians, numerous specialties
numerous specialties

Currency and Incentives
Reputation: trusted, independent, unbiased, 3rd party
Contagious passion and enthusiasm

Information
Funding

Activities
Influence direction
Foster collaboration
Change behavior and policy

Create knowledge: clinical evidence, best practices & standards
Cultivate the next generation
Convene the community
Collect and disseminate information
Increase awareness: communications
Overcome barriers

Influence Direction
Define areas of clinical benefit

Prioritize indications
Market oriented approach
 Segment to achieve natural advantage
 Pick battles
 Rapid success

Foster Collaboration
Rapidly achieve a critical mass of effort and knowledge
Approach
 Stimulate innovation
 Leverage intellectual capital
 Coordinate activities, avoid duplication

Change Behavior & Policy
Amalgamate stakeholders into a cohesive ecosystem
 Patient centric
 Sense of urgency

Develop Evidence of Safety, Efficacy
Organize, conduct and fund research
Niche: translational, application > discovery
 Preclinical, clinical, technical
 High risk, early stage, broad impact

Iconoclastic model
 Collaboration vs. individual glory
 Patient centric vs. investigator centric
 Commercially successful products vs. publications, grants, promotion

Programs, tightly managed, milestone driven
 External award: investigator initiated
• Competitive, peer reviewed

 Internal, Foundation initiated
• Brain, liver
• Contracts with academia, industry

Establish Best Practices, Set Standards
Research, training, patient care
Centers of Excellence: multidisciplinary luminary sites
 Showcase for technology
 Venue for collaboration

Partnership of academia, industry and the Foundation

Centers of Excellence
UVA Focused Ultrasound Center
 Partnership





University of Virginia
Commonwealth of VA
FUS Foundation
InSightec and GE

Institute for Cancer Research, London
 Partnership
 Royal Marsden Hospital
 FUS Foundation
 Philips Medical

Cultivate the Next Generation
Educate clinicians and scientists
Fund fellowships and internships

Convene the Community
Organize and fund meetings, symposia, workshops
 Exchange knowledge and ideas
 Foster collaborations and partnerships

Foundation Organized

Foundation Supported

Collect and Disseminate Knowledge
Website
Newsletter

Journal
Collaborative Network
Social Media

Website – fusfoundation.org
Encyclopedia of Focused Ultrasound

Source of information
 Comprehensive
 Trusted
 Up to date

Journal

Online, open access, peer reviewed
Partnership with International Society for Therapeutic Ultrasound

Collaborative Network
Inventory, updated quarterly on website





Laboratory research sites, investigators and projects
Clinical research sites
Commercial treatment sites
Manufacturers

Social Media
facebook.com/focusedultrasound

@FUSFoundation

Increase Awareness: Communications
Inform stakeholders, heat up environment, advance field
Awareness events

Media relations

Overcome Barriers
Regulatory: partner with FDA, bridge not a barrier
 Pathway for new indications: preclinical & clinical studies

Reimbursement: obtain coverage & payment
 Evidence of safety, efficacy, cost
 Patient advocacy
 Physician advocacy

Strategy
Leverage capital: Cofunding and funding, indirect costs, royalties
Best in class management practices
 Transparency, accountability
 Continuous quality improvement, policies, procedures, systems

Align vision, mission, strategy, organization, culture, resources
Prime the pump
 Engage Foundations, Government, Industry, VC's
 Assume functions of Foundation

Organization
Flat: flexible, responsive to market and technology shifts
17 Athletes, A-players





Unbounded, highly intelligent, highly educated
Healthcare professionals with over 140 years of experience
3 Ph.D.'s, 3 M.B.A.'s, 2 M.D.'s
Interns

Organized in teams

Portfolio of Programs
Research
Collaborative network

Educational fellowships
Meetings, symposia, workshops

Regulatory
Reimbursement
Communications
Website
Newsletter
Online, open-source journal

Accelerate development
and adoption

Board of Directors…active, engaged, passionate
Neal F. Kassell, M.D.

Edward D. Miller, M.D.

Chairman, Focused Ultrasound Foundation
Professor, Department of Neurosurgery, University of Virginia

Former CEO, Johns Hopkins Medicine

Dorothy N. Batten

Frederic H. Moll, M.D.

Former Director, Landmark Communications

Co-founder, Intuitive Surgical
Co-founder and Executive Chairman, Hansen Medical

S. Morry Blumenfeld, Ph.D.

Steve H. Rusckowski

Founding Partner, Meditech Advisors Management

CEO, Quest Diagnostics
Former CEO, Philips Healthcare

Eugene V. Fife

Lodewijk J.R. de Vink

Founding Principal, Vawter Capital

Founding Partner, Blackstone Health Care Partners

John R. Grisham

Andrew C. von Eschenbach, M.D.

Author

Daniel P. Jordan, Ph.D.
President Emeritus, Thomas Jefferson Foundation, Inc.

President, Samaritan Health Initiatives

Academic and Corporate Relationships
S. Morry Blumenfeld, Ph.D.
 InSightec, Shareholder

Neal F. Kassell, M.D.
 InSightec, Shareholder
 UVA, Faculty Member

Andrew C. von Eschenbach, M.D.
 Histosonics, Director and Shareholder

Council
Purpose
 Harness goodwill, increase awareness

Members
 Passionate, enthusiastic advocates
•
•
•
•
•
•
•
•
•
•
•
•

Jane P. Batten (Co-chair)
Charles H. Seilheimer, Jr. (Co-chair)
John B. Adams, Jr.
Ellen Block
Edgar M. Bronfman, Sr.
Thomas N. & Nancy J. Chewning
Norwood & Marguerite Davis
Diane Heller
Cecelia S. Howell
Dean L. Kamen
Robert Khayat, Ph.D.
Shirley Lin, Ph.D.

•
•
•
•
•
•
•
•
•
•
•
•

Amanda Megargel
Michael Milken
Paula Newcomb
Wyndham G. Robertson
Mary Lou Seilheimer
Alice H. Siegel
Aaron Stern, M.D., Ph.D.
Howard & Fredi Stevenson
Jack Syer
The Honorable Nicholas F. Taubman
Kitchie Tolleson
Linda K. Zecher

Resources – Financial Capital
Committed to date $54 million





62% from Individuals
24% from Corporations/Organizations
10% from Government
3% from Foundations

Next 3 years: invest additional $25 million






Research
Fellowships
Regulatory & Reimbursement
Symposium, Website, Newsletter, Journal

Fund Raising Model
Patients are impatient
Target venture philanthropists





Rapid decisions
Results oriented
Staying power
Substantial capacity (value every dollar, every donor)

Value Proposition
Once in a lifetime opportunity
 Investment with extraordinary return
 Social not economic

Big idea, compelling story, noble cause
Perfect timing
Best in class management practices

Results – Accelerating Adoption
Magic moment in evolution
 Opportunity to make a difference

Early stage
 Small investment = large impact

No major theoretical or technical barriers
 Development > Discovery

Brute force application of $

enormous progress

Accelerating Development and Adoption
2026 +$20
2024 +$35
2022 +$50 million
2020 +$65million
2028 2030
+$5
2013
Development

Adoption

Millions
of Lives
Improved

It’s all about the patients
It‟s all about the patients: Saving time, Saving lives
Saving time, Saving lives

Focused Ultrasound Manufacturers

Acublate

SJTU SUNTEC

Research and Commercial Treatment Sites
140+ Research sites
380+ Commercial treatment sites

2

Reimbursement
FDA
14
2
2

Other Approvals
Pivotal
Pilot
Anecdotal
Preclinical

14
4

Q3 2013

Conceptual

Dissolve Bloodclots: Sonothrombolysis

1/4


2/4


3/4


4/4

Procedure: Targeting

Structures
to be avoided

Region to be
treated

Procedure: Planning

Automatic planning

Procedure: Treatment

Temperature
measurement

Procedure: Guidance

Move to next target

Procedure: Confirmation
Pre treatment

Treatment plan

Post treatment

Internship Program

Back to Activities Slide

Back to Organization Slide

Procedure: Targeting

Structures to be avoided

Region to be treated

1/4

Procedure: Planning

Automatic planning

Manual adjustment

2/4

Procedure: Treatment

Real time guidance
Temperature measurement
Adjust treatment parameters

3/4

Procedure: Confirmation

Confirmation of effectiveness

Retreat if necessary

4/4

Post-treatment Confirmation

5/5

Unique
Accelerate development of device
Platform technology
 Multiple mechanisms of action
 Variety of medical disorders

116

Patient Support Organization
Advocacy Group: Grass Roots
 Increase Awareness
• Patients
• Physicians
• Insurers

Facilitate Reimbursement
Fibroid Relief: Prototype
FR Website – 71,000 visitors
since January 2009

117

Team
Mark Adcock
Rachel Browning
Matt Eames, Ph.D.
Jessica Foley, Ph.D.
Arik Hananel, M.D., M.B.A, BsCs
Melissa Healy
Sara Horton
Heather Huff-Simonin, M.B.A.
Robin Jones
Neal Kassell, M.D.
Susan Klees
Pamela Minetti, M.B.A.
Dave Moore, M.Sc.

Jill Roberts
Whitney Robertson
Mary Rose Serafini
John Snell, Ph.D.
Interns

118

Potential Impact, Urgent Need
Cumulative adoption

Without the
Foundation

With the
Foundation

2000

2010

2020

Millions of People

2030

Use of Funds







Research
Meetings, Symposia, Workshops
Fellowships
Reimbursement Initiative
Core Programs

$9 million
$1 million
$1 million
$1 million
$1 million
$7 million

120

Research
 External Awards

$2 million

 Parkinson‟s Disease

$2.4 million

 Brain Tumors

$850,000

 Pancreatic Cancer

$250,000

 Liver Cancer

$250,000

 Breast Cancer

$600,000

 Stroke

$600,000

 Epilepsy

$500,000

 Brain Technology

$800,000

 Back Pain

$500,000
$9 million
121

Management Practices
Highest standards, not-for-profit, for profit
 Best practices: policies, processes, systems
 Continuous Quality Improvement
 People

Strategic Plan
 Reviewed and updated frequently
 Acting > studying and planning

Culture
 Entrepreneurial, market driven, results oriented
 Patient centric: It‟s all about the patients

Operating plan and program management
 Updated annually, quarterly, weekly
1/3

122

Governance





Articles of incorporation, bylaws
Board of Directors; represent all stakeholders
Audit & compensation committees
Legal review

Finance






Monthly reporting with audit committee review
External audit of annual financials and 990
Annual 501(c)(3) tax status review
Prudent investment policy
Comprehensive insurance coverage

2/3

123

People






Philosophy: „A‟ players, athletes
Quarterly performance review against objectives
Biannual external compensation review
Structured hiring/termination process
Employee handbook

Research awards and contracts





Contracting: legal and sponsored program expertise
Peer reviewed: research advisory committee
Competitive: program funding committee
Monitoring: milestones, progress reports, payments

IT Infrastructure
 Backups, security, redundancy
3/3

124

Use of Funds








Research
Fellowships
Communications
Reimbursement
Miscellaneous
Development

$9.6 million
$1.4 million
$4.1 million
$3.6 million
$1.8 million
$400,000
$2.2 million
$23 million

125

Individual Donors (updated 9/19/12)
Anonymous
Bob and Glorie Bailie
Baker Construction Group
Aimee and Frank Batten, Jr. Foundation
D.N. Batten Foundation
Frank* and Jane Batten
Mr. and Mrs. David A. Beach
Anson and Debra Beard
The Bernstein Law Firm, LLC
Ms. Lois Berry
Birdsall Family Fund
Ellen and Ronald Block Family Foundation
Dr. and Mrs. S. Morry Blumenfeld
Rich and Roxanne Booth
Charles R. Bronfman
Edgar M. Bronfman and Jan Aronson
Peter and Nancy Brooks
Scott Byron and Company, Inc.
Phebe Cambata
The Caruthers Foundation
Mr. and Mrs. Norton E. Cater
Mr. and Mrs. John Chamales
Roy R. Charles Charitable Trust
Derwood and Johanna Chase

Tom and Nancy Chewning
Christian Broadcasting Network, Inc.
Moffett and Dupre Cochran
Mr. and Mrs. Victor M. Dandridge, Jr.
Mr. and Mrs. Terrence D. Daniels
Mr. and Mrs. John Stewart Darrell
Mrs. Margareta C.H. Douglas*
Mrs. Francis Dulaney
Joan and Barry Elman
Mr. and Mrs. Albert D. Ernest
Fibroid Foundation
Eugene V. Fife Family Foundation
Bruce D. Fisher
Margaret and Thomas Flynn
Penny and John Freund
Mr. and Mrs. Donald Geller
Struthers and Frederick Gignoux
Mark and Judy Giles
Leslie and Richard Gilliam
Mr. and Mrs. Donald Goldsmith
Ms. Audrey Gould
Julann Griffin
Marge and Joe Grills
Mr. and Mrs. Eugene R. Hack, Jr.

1/3

126

Jim and Sue Haden
Carolyn Hadesman and Family
John A. Hartford Foundation, Inc. Matching Gift Program
The Hassenfeld Foundation
Diane and David* Heller
Herndon Foundation
Mary Buford and Frederick P. Hitz
The Joseph M. and Lisa B. Hogan Charitable Fund
Ulrike Hoffmann-Burchardi and Dirk Willes
Horton Foundation Fund in CACF
The Horwich Family Foundation
Mr. and Mrs. Robert M. Huff
Chad D. Inman
Dean Johnson
Mr. Thomas N.P. Johnson, III
Lou and Dan Jordan
Drs. Neal and Lee Kassell
Marcia and Jonathan Kean
The Keeley Family Foundation
The Kellogg Organization, Inc.
Mr. and Mrs. Donald A. King, Jr.
Mr. and Mrs. Douglas M. Kinney
Mr. James B. Klutznick
Mrs. Delores J. Kuberka
Mr. and Mrs. Fritz R. Kundrun

Diana Levin
Lawrence and Carol Levy
Dr. Stanley H. Levy
John L. Lewis, IV
Mr. and Mrs. Harvey L. Lindsay, Jr.
Terry J. Lockhart
Mr. and Mrs. John Lucey
St. Luke‟s Hospital
John and Dudley MacFarlane
Chrisanne Mannion
Paul and Diane Manning
Jill Kiersky and Andrew Marcus
Mr. and Mrs. Donald Mazzoni
Janice McArdle Cancer Research Foundation
Patrick McCarthy
Melville Foundation
Methodist Hospital
Milken Family Fund
Mitford Children‟s Foundation
Frederic Moll
Mr. and Mrs. Victor A. Morgenstern
Thos. Nelson Jr. Initiative of the Community Foundation
Serving Richmond and Central Virginia
Paula and Rob Newcomb
Dick and Judy Nunley

2/3

127

Joy Marie Polefrone
Prince Charitable Trusts
Dr. M.G. Pat Robertson
The Robertson Foundation
Wyndam Robertson
Mr. and Mrs. Thomas C. Rodeno
Felicia W. Rogan
Madison Rogers
Harry and Ady Rosenberg
Mr. and Mrs. Charles M. Rotgin
Steve and Deborah Rusckowski
Mr. Raymond L. Rusnak
Cari and Michael Sacks
The Adler Schermer Foundation
Valerie Beth Schwartz Foundation
Mr. and Mrs. Charles H. Seilheimer, Jr.
Linda Rae Sher
Rick and Sherry Sharp, The Community Foundation
Dr. James A. Shield, Jr.
Alice H. Siegel
Mr. and Mrs. Thomas A. Silberman
Jane-Ashley and Peter Skinner
Albert H. Small
The Eddie and Jo Allison Smith Family Foundation, Inc.

Oscar F. Smith/Marjorie Smith Charles Charitable Fund of
the Community Serving Richmond and Central Virginia
Robert H. Smith Family Foundation
Mr. and Mrs. Francis M. Stanis
Barbara and Cyrus Sweet III
Virginia and John Syer
Fay Davis Taylor In Memory of Bertrand L. Taylor III
Sandra Thomas
Jane Tolleson
Ms. Cecile Trop
Sarah Beck and Wojtek Uzdelewicz
Eleanor Cameron Van Clief Foundation
Mrs. Faith Van Clief
Sheri Waddell
Mr. and Mrs. Herbert S. Wander
Mark Warner and Lisa Collis
The Watterson Foundation
R. Ted and Sheila Weschler
Custis Westham Fund of the Community Foundation
Jane Woldenberg Family Foundation
Laurie and Bruce Zessar
Michael Zoller Family Philanthropic Fund

3/3

128

Corporate Donors and Sponsors
Abbott Laboratories
Cooley Godward Kronish
Crutchfield Corporation
EDAP
Elbit
Elekta
GE Healthcare
IGT
Imasonic
InSightec
International Society for
Therapeutic Ultrasound (ISTU)
JJA Instruments
JP Morgan

The Kellogg Organization, Inc.
Meditech Advisors
Methodist Hospital
Microsoft
Ogilvy Public Relations
Philips Healthcare
Siemens
St. Luke‟s Hospital
Supersonic Imagine
Theraclion
University of Virginia
Varian Medical Systems Foundation

129

Process, complicated and inefficient
Patient
advocacy

Evidence, safety,
efficacy, cost

Technology R&D
IP generation
and protection

Design, engine
ering,
manufacturing
Pre-clinical
proof of concept

Regulatory
approval

Marketing,
sales, support

Training and
credentialing

Insurance
reimbursement

Physician and
Scientist education

Physician
advocacy

Uterine Fibroids
before treatment

planning

post-treatment

Approved: FDA 2004, CE: 2003

Pain Palliation of Bone Metastases
Patient with osteolytic breast cancer metastasis at right iliac bone
Pain score of 5.5 before treatment reduced to 0 at 3M follow up
CT Before Treatment

Note: At 3M new bone formation and thickening
of cortical layer in treatment area

Prostate Cancer - Transurethral

Liver Tumors

post treatment dose maps
(in blue)
and post treatment T1W C

Facet Rhizotomy
Focused ultrasound energy treats in the same
locations as RF ablation

Neuropathic Pain – Zurich Research

Brain Tumors
Accumulated thermal dose
at end of treatment

Diffusion weighted image
immediately after treatment

T1w contrast enhanced image
immediately after treatment

Focused Ultrasound Foundation

FUSF

Fusf presentation to share 11.20

Recommended

Recommended

More Related Content

What's hot

What's hot (20)

Viewers also liked

Viewers also liked (17)

Similar to Fusf presentation to share 11.20

Similar to Fusf presentation to share 11.20 (20)

Recently uploaded

Recently uploaded (20)

Fusf presentation to share 11.20

Editor's Notes